Summary
The antiproliferative potency of mitoxantrone (MITOX) has predominatly been established for epithelial and hematologic neoplasias. In this study the effectiveness of MITOX was investigated in vitro for 6 sarcomatous human cell lines derived from 2 synovial sarcomas, a malignant schwannoma, a malignant histiocytoma, a leiomyosarcoma, and a chondrosarcoma. The examination was performed using a proliferation assay with monolayer cell cultures. The effect of MITOX was compared with that of adriamycin (ADR) and cisplatin (CDDP). For each drug at least 3 concentrations were tested which covered the therapeutically achievable range, i.e., for MITOX 0.2–0.002 μg/ml, for ADR 0.5–0.005 μg/ml, and for CDDP 5.0–0.05 μg/ml. Test incubations were performed for 3 days. Antiproliferative potency of the cytostatic drugs was assessed by counting the number of cells at the start and the end of the test period with and without drug addition. Furthermore the dose inhibiting cell growth to 50% of controls (ID50) was determined for MITOX. For comparison 4 cell lines from carcinomatous lesions were included in the study. MITOX inhibited proliferation rates of 4 sarcomatous tumor cell lines more intensively than ADR, and was less effective in 2 cell lines. However, these differences were not significant. In all mesenchymal cell lines tested the antiproliferative potency of MITOX was more pronounced than that of CDDP. In carcinomatous cell lines the MITOX-induced growth inhibition was similar to that found in response to administration of ADR and CDDP confirming the described effect on epithelial tumors. The study suggests that MITOX possesses a growth inhibitory potency for malignant soft tissue tumors in vitro. From these data it may be worthwhile to initiate clinical trials testing the treatment of sarcomatous lesions with MITOX.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Albrecht M, Simon WE, Hölzel F (1985) Individual chemosensitivity of in vitro proliferating mammary and ovarian carcinoma cells in comparison to clinical results of chemotherapy. Cancer Res Clin Oncol 109:210–216
Alberts DS, Yei-Mei Peng, Leigh S, Davis TP, Woodward DL (1984) Disposition of mitoxantrone in patients. Cancer Treat Rev 10 (Suppl B):23–27
Arps H, Bals U, Gerding D, Niendorf A, Garbrecht M, Klapdor R, Hölzel F, Dietel M (1987) In vitro test for chemosensitivity using freshly explanted tumor cells. Int J Immunotherapy 3:229–235
Bezwoda WR, Hesdorffer C (1986) The use of mitoxantrone plus cyclophosphamide as first-line treatment of metastatic breast cancer. Cancer 58:1621–1624
Bull FE, Von Hoff DD, Balcerzak SP, Stephens RL, Panettiere FJ (1985) Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study. Cancer Treat Rep 69:231–233
Cohen LF, Glaubiger DL, Kann HE, Kohn KW (1980) Protein-associated DNA single strand breaks and cytotoxicity of dihydroxyanthracenediona (DHAD), NCS-301739, in mouse L1210 leukemia cells. Proc Am Assoc Cancer Res (Abstr) 21:277
Coltman CA, McDaniel, Balcerzak SP, Morrison FS, von Hoff DD (1983) Mitoxantrone hydrochloride (NSC-310739) in lymphoma. Invest New Drugs 1:65–70
Dalton WS, Alberts DS (1984) Physiologic disposition and phase I studies of mitoxantrone. In: Smyth JF (ed) A comprehensive guide to the therapeutical use of Novantrone. PharmaLibri, Chicago, pp 75–86
Darzynkiewicz Z, Kapuscinski J, Carter SP, Schmid FA, Melamed MR (1986) Cytostatic and cytotoxic properties of pyronin Y: relation to mitochandrial localization of the dye and its interaction with RNA. Cancer Res 46:5760–5766
Dietel M, Arps H, Klapdor R, Müller-Hagen S, Sieck M, Hoffmann L (1986a) Antigen detection by the monoclonal antibodies CA 19–9 and CA 125 in normal and tumor tissue and patients' sera. Cancer Res Clin Oncol 111:257–265
Dietel M, Arps H, Rohlff A, Bodecker R, Niendorf A (1986b) Nuclear DNA content of borderline tumors of the ovary: correlation with histology and significance for prognosis. Virchows Arch (A) 409:829–836
Dietel M, Arps H, Albrecht M, Simon WE, Klapdor R, Gerding D, Trapp M, Hölzel F (1986c) Predictive determination of the sensitivity of gastrointestinal carcinomas to cytostatic drugs using the in vitro monolayer proliferation assay. In: Klapdor R, Greten H (eds) Clinical relevance of new monoclonal antibodies. Thieme, Stuttgart New York, pp 447–455
Dietel M, Arps H, Gerding D, Trapp M, Niendorf A (1987a) Establishment of primary cell cultures: Experiences with 155 cell strains. Klin Wochenschr 65:507–512
Dietel M, Arps H, Niendorf A, Hölzel F (1987b) Effectiveness of ifosfamide on human tumor cells in culture using a monolayer proliferation assay. In: Brade P, Nagel GA, Seeber S (eds) Ifosfamide in tumor therapy. Karger, Basel, pp 60–68
Durr FE (1984) Preclinical studies with Mitoxantrone. In: Smyth JF (ed) A comprehensive guide to the therapeutical use of Novantrone. Pharma Libri, Chicago, pp 1–24
Ehninger G, Stocker H, Wilms K (1981) Metabolisierung und Ausscheidung von Adriamycin. In: Füllenbach D, Nagel GA, Seeber S (Hrsg) Beitr Onkol 9, Karger, Basel, S 16–25
Ehninger G, Proksch B, Heinzel G, Woodward DL (1985) Klinische Pharmakologie und Pharmakokinetik. In: Nagel GA (Hrsg) Mitoxantron. Ein neues Zytostatikum. Aktuelle Onkologie 18. Zuckschwerdt, München Bern Wien, S. 3–13
Hölzel F, Albrecht M, Simon WE, Hänsel M, Metz R, Schweizer J, Dietel M (1985) Effectiveness of antineoplastic drugs on the proliferation of human mammary and ovarian carcinoma cells in monolayer culture. Cancer Res Clin Oncol 109:217–226
von Hoff DD, Pollard E, Kuhn J, Murray E, Coltman CA Jr (1980) Phase I clinical investigations of 1,4-dihydroxy-5,8-bis((2-((2-dihydroxyethyl)amino)ethyl)amino)-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione. Cancer Res 40:1516–1518
von Hoff DD, Coltman CA Jr, Forseth B (1981) Activity of mitoxantrone in a human tumor cloning system. Cancer Res 41:1853–1855
Litterst CL, LeRoy AF, Guarino AM (1979) Disposition and distribution of platinum following parenteral administration of cisdichlorodiammineplatinum(II). Cancer Treat Rep 63:1485–1492
Knight WA, von Hoff DD, Neidhart JA, Tranum BL, Fabian C, Jones SE (1983) Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group. Invest New Drugs 1:181–184
Paciucci PA, Ohnuma T, Cuttner J, Silver RT, Holland JF (1983) Mitoxantrone in patients with acute leukemia in relapse. Cancer Res 43:3919–3922
Presant CA, Gams R, Bartolucci A (1984) Treatment of metastatic sarcomas with mitoxantrone. Cancer Treat Rep 68:813–814
Pratt CB, Etcubanas E, Thompson E, Hayes FA, Champion JE, Crom DB (1982) Mitoxantrone (dihydroxyanthracenedione, DHAD)-phase II study in pediatric patients. Proc Am Assoc Cancer Res (Abstr) 23:122
Salmon SE (1985) Predictive models for anticancer activity. In: Salmon SE, Ogawa M (eds) Rational development of a new anticancer agent. Proc 14th Int Congr Chemotherapy (Kyoto), pp 5–9
Salmon SE, Hamburger AW, Soehnlein B, Durie BGM, Alberts DS, Moon TE (1978) Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. N Engl J Med 298:1321–1327
Seeber S (1981) Molekulare, zelluläre und klinische Pharmakologie von Adriamycin. In: Füllenbach D, Nagel GA, Seeber S (Hrsg) Beitr Onkol 9. Karger, Basel S. 1–15
DeSimone PA, Gams R, Bartolucci (1986) Weeky mitoxantrone in the treatment of advanced pancreatic carcinoma: a southeastern cancer study group trial. Cancer Treat Rep 70:929–933
Shenkenberg TD, von Hoff DD (1986) Mitroxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 105:67–81
Traganos F, Evenson DP, Staiano-Coico L, Darzynkiewicz Z, Melamed MR (1980) Action of dihydroxyanthraquinone on cell cycle progression and survival of a variety of cultured mammalian cells. Cancer Res 40:671–681
White RJ, Durr FE (1985) Development of mitoxantrone. Invest New Drugs 3:85–93
Author information
Authors and Affiliations
Additional information
This work was supported by the Hamburger Stiftung zur Förderung der Krebsbekämpfung, the Hamburger Landesverband zur Krebsbekämpfung und Krebsforschung and the E. und G. Roggenbruck-Stiftung
Rights and permissions
About this article
Cite this article
Dietel, M., Arps, H., Gerding, D. et al. Effectiveness of mitoxantrone on the proliferation of cell cultures derived from malignant mesenchymal tumors of human origin. J Cancer Res Clin Oncol 114, 197–203 (1988). https://doi.org/10.1007/BF00417837
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00417837